Efficacy and safety of guselkumab in patients with ... | 合法藥品大搜索

由ADeodhar著作·2018·被引用121次—Interpretation:Guselkumab,anovelanti-interleukin23p19antibody,significantlyimprovedsignsandsymptomsofactivepsoriaticarthritisand ...

Background: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis.

Methods: We did a randomised, double-blind, placebo-controlled, phase 2a trial at 34 rheumatology and dermatology practices in Canada, Germany, Poland, Romania, Russia, Spain, and the USA. Eligible participants were aged 18 years or older with active psoriatic arthritis and plaque psoriasis affecting at least 3% of their body surface area, with three or more of 66 tender joints and three or more of 68 swollen joints, who had an i...